The shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) has been pegged with a rating of Outperform by SVB Leerink in its latest research note that was published on March 29th, 2019. The research company has also assigned a $21 price target. SVB Leerink wasn’t the only research firm that published a report of Viking Therapeutics, Inc., with other equities research analysts also giving their opinion on the stock. Maxim Group advised investors in its research note published on March 14th, 2019, to Buy the VKTX stock while also putting a $20 price target. The stock had earned Mkt Perform rating from SVB Leerink when it published its report on February 22nd, 2019. The stock was given Buy rating by B. Riley FBR in its report released on December 12th, 2018, the day when the price target on the stock was placed at $16. Raymond James was of a view that VKTX is Strong Buy in its latest report on November 19th, 2018. Raymond James thinks that VKTX is worth Outperform rating. This was contained in the firm’s report on September 18th, 2018 in which the stock’s price target was also moved to $43.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $27.00. The price of the stock the last time has raised by 170.19% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 57.17.
The shares of the company dipped by -1.58% during the trading session on Thursday, reaching a low of $9.81 while ending the day at $9.97. During the trading session, a total of 9.77 million shares were traded which represents a -195.97% decline from the average session volume which is 3.30M shares. VKTX had ended its last session trading at 10.13. Viking Therapeutics, Inc. currently has a market cap of $696.80M, with a beta of 2.74. Viking Therapeutics, Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 66.40. VKTX 52-week low price stands at $3.69 while its 52-week high price is $24.00.
The company in its last quarterly report recorded -$0.07 earnings per share which is above the -$0.10 predicted by most analysts. In the second quarter last year, the firm recorded -$0.11 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -57.14%. Viking Therapeutics, Inc. has the potential to record -0.39 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Jefferies published a research note on January 29th, 2019 where it informed investors and clients that Visa Inc. (NYSE:V) is now rated as Buy. Maxim Group also rated V as Reiterated on March 14th, 2019, with its price target of $20 suggesting that V could surge by 3.66% from its current share price. Even though the stock has been trading at $158.56/share, analysts expect it to surge higher by -0.44% to reach $163.86/share. It started the day trading at $159.30 and traded between $157.44 and $157.86 throughout the trading session.
A look at its technical shows that V’s 50-day SMA is 149.62 while its 200-day SMA stands at 142.00. The stock has a high of $159.11 for the year while the low is $119.37. The company’s P/E ratio currently sits at 33.93, while the P/B ratio is 12.17. At the moment, only of Visa Inc. shares were sold short. The company’s average trading volume currently stands at 8.51M shares, which means that the short-interest ratio is just 3.64 days. Over the past seven days, the company moved, with its shift of 0.14%. Looking further, the stock has raised 13.84% over the past 90 days while it gained 10.93% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more V shares, increasing its portfolio by +1.01% during the last quarter. This move now sees The Vanguard Group Inc purchasing 1,319,006 shares in the last quarter, thus it now holds 131,606,930 shares of V, with a total valuation of $20,555,686,397. Fidelity Management Research Co meanwhile bought more V shares in the recently filed quarter, changing its stake to $13,541,644,261 worth of shares. BlackRock Fund Advisors followed the path by increasing its V portfolio by +0.56% in the quarter. This means that BlackRock Fund Advisors bought 463,336 shares in the last quarter and now controls 83,329,034 shares of the V stock, with the valuation hitting $13,015,161,820.
Similarly, SSgA Funds Management Inc decreased its Visa Inc. shares by -1.94% during the recently filed quarter. After selling -1,508,438 shares in the last quarter, the firm now controls 76,199,273 shares of Visa Inc. which are valued at $11,901,564,450. In the same vein, Massachusetts Financial Services decreased its Visa Inc. shares by during the most recent reported quarter. The firm sold -553,278 shares during the quarter which decreased its stakes to 30,267,210 shares and is now valued at $4,727,435,530. Following these latest developments, around 0.10% of Visa Inc. stocks are owned by institutional investors and hedge funds.